JPRN-jRCTs021200005进行中（未招募）2 期
A phase II study of afatinib in combination with pemetrexed and carboplatin in Japanese patients with EGFR mutation positive (mEGFR+) non-squamous (SQ), advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment. - NEJ025B
Maemondo Makoto0 个研究点目标入组 35 人开始时间: 2020年5月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)A histologically or cytologically confirmed diagnosis of non-small-cell lung cancer other than squamous cell carcinoma.
- •2)Have clinical stage IIIB, IIIC, IVA, IVB or postoperative recurrent non-small-cell lung cancer that cannot be treated with radical radiotherapy and surgery.
- •3)An observed Exon 19 deletion mutation or Exon 21 L858R mutation in tumor tissue or tumor cells before osimertinib treatment.
- •4)They have 1 or more measurable lesions based on the criteria in Response Evaluation Criteria in Solid Tumors (RECIST)Version 1.1 after failure of osimertinib.
- •5)Confirmed PD of previous osimertinib treatment as a first-line treatment. Regardless of treatment duration of osimertinib.
- •6)Recovering from adverse effect until grade1 or less.
- •7) Be a case where chemotherapy or immunotherapy has not yet been carried out, excluding neoadjuvant and adjuvant chemotherapy 6 months before enrollment and pleurodesis a week before enrollment.
- •8)Be aged 20 years or over at the time of consent acquisition.
- •9)Have an ECOG performance status (PS) of 0 to 1.
- •10)Main organ functions must meet the following criteria within two weeks prior to enrollment. If there are multiple test results within this period, then the most recent test prior to enrollment will be adopted.
- •1) Neutrophil count 1,500/mm3 or above
- •2)Lymphocyte count 500/mm3 or above
- •3)Hemoglobin 9.0 g/dL or above
- •4)Platelet count 10.0 x104/mm3 or above
- •5)AST 2.5 times the upper limit of the site's standard values or below
- •6)ALT 2.5 times the upper limit of the site's standard values or below
- •7)Total bilirubin 1.5 times the upper limit of the site's standard values or below
- •8)Serum creatinine 1.5 times the upper limit of the site's standard values or below
- •9)Creatinine Clearance 45 mL/min or above
- •10) PaO2 (room air) 70 Torr or above, or SpO2 93% or above
- •11) The details of this study were sufficiently explained to the patient and written consent was obtained from the patient them self.
排除标准
- •1)Have active interstitial lung disease, or a history of drug-induced pneumonitis, radiation pneumonitis needing steroid treatment.
- •2)The patient has brain metastasis that requires anti-edema drugs such as steroids for symptomatic brain metastases or symptom management and meningitis carcinomatosa.
- •*Asymptomatic brain metastasis is not excluded.
- •3) Have a history of irradiation directed at the lesions in the lung field or other target lesion.
- •*Enrollment is permitted in cases which have had palliative irradiation for bone lesions in the chest, if at the time of enrollment 2 weeks or more have elapsed since the final day of irradiation.
- •4) Currently have serious complications including uncontrolled lung, liver, and renal disease.
- •5)Have heart disease that could be clinically problematic (such as uncontrollable hypertension, unstable angina, congestive heart failure, advanced arrhythmia requiring treatment with medication, or a history of myocardial Infarction within 12 months prior to enrollment).
- •* treatment of hypertension is eligible.
- •6) Currently have or have a history of the following serious complications:
- •-Also have superior vena cava syndrome.
- •-Have spinal cord compression.
- •-Also have symptomatic cerebrovascular disease or have a history of cerebrovascular disease within 3 months before enrollment.
- •-Have unhealed bone fractures (excluding the like associated with osteoporosis) or advanced wounds
- •-Have infectious diseases requiring systemic administration of antibiotics, antifungal agents or antiviral agents.
- •7) Have uncontrolled gastrointestinal disturbances affecting intestinal absorption of afatinib (such as Crohn's disease, ulcerative colitis, chronic diarrhea, and malabsorption).
- •8)Have an active hepatitis being positive for HBV DNA* and HIV infection.
- •*Measure HBV DNA if the patient is positive for HBs antigens, HBs antibodies or HBc antibodies
- •9) Women who are currently pregnant or breastfeeding. Or women who are capable of becoming pregnant. Men who want to partner's pregnancy.
- •10) Be undergoing systemic administration of steroids for 4 weeks or more (however, enrollment is permitted for steroids in terms of within prednisolone 10 mg/day).
- •11)Have pleural effusion, ascites or pericardial effusion that require drainage (enrollment is permitted if the symptoms stabilize a week after drainage).
- •12) Have contraindication to afatinib, carboplatin, or pemetrexed.
- •13) The patient has complications with double cancers that have a disease-free period of less than 5 years (enrollment is permitted if intraepithelial carcinoma and intramucosal carcinoma lesions have been judged as cured from localized treatment regardless of the disease-free period).
- •14) Have significant neuropathy or psychosis (includes dementia and epileptic seizures).
- •15) Surgery is planning during study period.
- •16) Have serious hypersensitivity to afatinib, carboplatin, or pemetrexed.
- •17) Individuals who are deemed to be unsuitable for participation in this study by the principal investigator or sub-investigators for any other reason.
研究者
相似试验
进行中（未招募）
1 期
Afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancerPatients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment failed.MedDRA version: 21.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001855-22-NLetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital140
进行中（未招募）
1 期
Afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancerEGFR exon 20 insertion positive non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001521-97-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis37
已完成
2 期
Phase II single arm study of afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancer10038666non-small cell lung cancerlung cancerNL-OMON55757Antoni van Leeuwenhoek Ziekenhuis37
招募中
不适用
Phase 2 study of afatinib in patients with previously treated advanced non-sq NSCLC haboring EGFR mutatioJPRN-UMIN000014981Gunma University Graduate School of Medicine55
已完成
2 期
Phase II Study of First-Line Afatinib in Patients Aged 75 or Older With Advanced Lung Adenocarcinoma With EGFR MutationsElderly patients with NSCLC harboring sensitive EGFR mutationJPRN-UMIN000015834Osaka Lung Cancer Study Group38